GSK PLC beats quarterly earnings estimates as the company reaffirms 2026 growth guidance
GSK PLC reported quarterly earnings of $1.36 per share, surpassing the Zacks Consensus Estimate of $1.27 per share. The drug developer posted revenues of $11.28 billion for the quarter ended June 2026, which exceeded expectations by 4.76%. While total operating profit fell by 75% due to higher impairments, core operating profit grew by 7% and core earnings per share rose by 9%. To support long-term growth, the company is launching a three-year cost savings program aimed at achieving £1.9 billion in annual savings by 2029. Management also announced the establishment of a new flagship R&D Centre on the UK's Cambridge Biomedical Campus. The company reaffirmed its 2026 guidance, expecting turnover growth of 3% to 5% and core earnings per share growth of 7% to 9%. GSK PLC remains on track for a 2031 sales outlook of more than £40 billion.